Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

Eligibility Criteria

• 1. Adult (≥ 18 years) female or male subjects.
• 2. Confirmed symptomatic proximal or distal lower extremity deep venous thrombosis with or without pulmonary embolism or other venous thromboses. For a symptomatic lower extremity deep venous thrombosis confirmed by compression ultrasonography, venography, or specific computerized tomography (CT) venography, or a thrombus detected in the iliac veins on an abdominal or pelvic CT. For symptomatic pulmonary embolism confirmed by computerized tomographic pulmonary angiography, ventilation perfusion scan, or catheter pulmonary angiography.
• 3. Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either active or diagnosed within 2 years prior to VTE. The diagnosis of cancer must be objectively documented by histopathologic diagnosis.
• 4. Intention for long-term treatment (at least 3 months) with anticoagulation.
• 5. Participants will be enrolled in the study within the first 72 hours from initiation of anticoagulation.
• 6. Able to provide informed consent and complete study survey tools
• 7. Able to read and speak English.
• 1. Indication for anticoagulation other than cancer-related VTE.
• 2. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 4 at the time of study enrollment.
• 3. Life expectancy \< 3 months.
• 4. Isolated pulmonary embolism, or isolated upper extremity deep venous thrombosis, or isolated splanchnic venous thrombosis, or isolated cerebral venous thrombosis confirmed by compression ultrasonography, venography, or CT.